Dr. Ronald G. Nahass, president of ID Care and the Infectious Diseases Society of America commented on encouraging findings from a Phase 2 study he coauthored presented at the 2025 European AIDS Clinical Society Conference showing that a once-weekly oral regimen combining islatravir and lenacapavir maintained viral suppression through two years. The latest data demonstrated that participants who switched from daily antiretroviral therapy to the weekly oral combination continued to have undetectable HIV-1 viral loads at 96 weeks, with high adherence and no observed emergent resistance — a potential advance in reducing treatment burden for people living with HIV-1.
Dr. Nahass emphasized that simplified, evidence-based therapeutic options can support long-term viral suppression, improve quality of life and address challenges associated with daily dosing regimens. His perspective reinforces the importance of robust clinical research and thoughtful evaluation of emerging HIV treatments as the field continues to innovate.
Read full story on the European AIDS Treatment Group website.